Background-Increased permeability, predominantly controlled by endothelial junction stability, is an early event in the deterioration of vascular integrity in ischemic disorders. Hemorrhage, edema, and inflammation are the main features of reperfusion injuries, as observed in acute myocardial infarction (AMI). Thus, preservation of vascular integrity is fundamental in ischemic heart disease. Angiopoietins are pivotal modulators of cell-cell junctions and vascular integrity. We hypothesized that hypoxic induction of angiopoietin-like protein 4 (ANGPTL4) might modulate vascular damage, infarct size, and no-reflow during AMI. Methods and Results-We showed that vascular permeability, hemorrhage, edema, inflammation, and infarct severity were increased in angptl4-deficient mice. We determined that decrease in vascular endothelial growth factor receptor 2 (VEGFR2) and VE-cadherin expression and increase in Src kinase phosphorylation downstream of VEGFR2 were accentuated after ischemia-reperfusion in the coronary microcirculation of angptl4-deficient mice. Both events led to altered VEGFR2/VE-cadherin complexes and to disrupted adherens junctions in the endothelial cells of angptl4deficient mice that correlated with increased no-reflow. In vivo injection of recombinant human ANGPTL4 protected VEGF-driven dissociation of the VEGFR2/VE-cadherin complex, reduced myocardial infarct size, and the extent of no-reflow in mice and rabbits. Conclusions-These data showed that ANGPTL4 might constitute a relevant target for therapeutic vasculoprotection aimed at counteracting the effects of VEGF, thus being crucial for preventing no-reflow and conferring secondary cardioprotection during AMI. (Circulation. 2012;125:140-149.)
contributor to myocardial damage after ischemic events. 1 Vascular damage also contributes to inadequate myocardial perfusion (the "no-reflow" phenomenon), which is observed in 30% of patients and is associated with a worse prognosis at follow-up and higher incidence of death. 2, 3 Prevention of vascular leak and edema improves flow during reperfusion post-AMI. 4 Enhancing myocardial flow therefore represents a pertinent strategy to improve ongoing therapies that might limit infarct size, ameliorate cardiac function, and prolong survival. 5 Treatments that minimize microvascular damage should be prioritized to protect the injured myocardium as recommended by guidelines set by the American College of Cardiology/American Heart Association. 6, 7 However, pharmacological treatment that targets microvascular dysfunction and inhibits the no-reflow phenomenon after reperfusion is not available. 3 
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Angiopoietins are major regulators of angiogenesis and vascular leakage through binding to the Tie2 receptor. Angiopoietin-1 promotes vessel maturation, whereas angiopoietin-2 destabilizes interactions between the cells of the vascular wall 8, 9 responsible for endothelial barrier disruption and vascular leakage. 10 Angiopoietin-like proteins (ANGPTL1-7) share structural and functional properties with angiopoietins but do not bind to the Tie2 receptor. Angiopoietin-like protein 4 (ANGPTL4) is a secreted 55-kDa protein that is processed in 20-kDa and 35-kDa forms. 11, 12 It is a dual-function protein: an inhibitor of lipoprotein and hepatic lipases, [13] [14] [15] with angiogenic properties. We have shown that its expression is induced by hypoxia in vascular cells in ischemic diseases. 16 ANGPTL4 is a tissue-specific modulator of vascular permeability [17] [18] [19] that regulates the survival and adhesion of endothelial cells (ECs) in vitro 20, 21 and angiogenesis in vivo. 16, 17 In humans, ANGPTL4 possesses several variants, including the inactive E40K variant, which is associated with significantly lower plasma levels of triglycerides and higher levels of high-density lipoproteins. 22 Interestingly, individuals carrying the E40K variant display an atheroprotective lipid profile, but they are subjected to an increased risk of coronary heart disease. 23 We show here that ANGPTL4 expression is induced in response to myocardial infarction in humans and mice. The goal of the present study was to analyze the role that ANGPTL4 might play in this context. Indeed, ANGPTL4 is expressed by cardiomyocytes, 24, 25 but also in ECs in response to hypoxia, and it could modulate vascular permeability. In a model of myocardial ischemia-reperfusion, we show that angptl4-deficient mice display (1) increased size of myocardial infarcts, (2) increased no-reflow, (3) decreased vascular integrity through Src-dependent dissociation of the VEGFR2/ VE-cadherin complex and subsequent destabilization of endothelial adherens junctions, and (4) increased hemorrhage and inflammation. In addition, we show that recombinant human ANGPTL4 (rhANGPTL4) has therapeutic potential in reducing no-reflow, hemorrhage, and infarct size after myocardial infarction in mice and in a nonrodent species (rabbit). These data therefore provide evidence that vasculoprotection through ANGPTL4 is a relevant therapeutic approach to confer secondary cardioprotection in AMI.
Materials and Methods
The experiments were performed in accordance with the guidelines of the French Ministry of Agriculture. This study conforms to the standards of INSERM (the French National Institute of Health) in accordance with European Union Council Directives (86/609/EEC). All experiments were performed blindly, meaning that the experimenter was blind to the mouse genotype.
Animals and Genotyping
Angptl4 LacZ/LacZ mice in which the angptl4 locus was replaced by a lacZ reporter gene were generated 26 and genotype was determined by the polymerase chain reaction of tail genomic DNA. 27 Eight-to 12-week-old angptl4 LacZ/ϩ and angptl4 LacZ/LacZ knockout male mice, intercrossed in C57/Bl6 mice for Ͼ8 generations, were subjected to myocardial infarction protocols or used as control in basal conditions.
Myocardial Ischemia-Reperfusion Experiments
Ischemia-reperfusion protocol was performed on angptl4 LacZ/ϩ and angptl4 LacZ/LacZ mice or rabbits by using a standard technique described in the online-only Data Supplement Materials. Mice and rabbits randomly received either vehicle or human recombinant 55-kDa full-length ANGPTL4 12 (rhANGPTL4 10 g/kg IV).
Modified Miles Assay
Male angptl4 LacZ/LacZ and angptl4 LacZ/ϩ mice were anesthetized with the use of pentobarbital. Under basal conditions, mice were injected into the tail vein with 1% Evans blue (200 L) and euthanized 4 hours later. After ischemia-reperfusion, mice were subjected to coronary occlusion for 45 minutes and intravenously injected with 1% Evans blue (200 L) before the 4 hours of reperfusion. At euthanization, mice were perfused through the aorta with citrate buffer, pH4. Blood, dye, and buffer exited through an opening in the right atrium. Evans blue was eluted for 18 hours at 70°C in 1 mL of formamide. After centrifugation, absorbance at 620 nm was measured by using a spectrophotometer. Extravasated Evans blue (ng) was determined from a standard curve and normalized to tissue weight (g).
Immunofluorescence Study and Confocal Analysis on Cryosections
Immunofluorescence staining was performed as previously described, 28 and confocal analysis on cryosections is detailed in the online-only Data Supplement Materials.
Immunoprecipitation and Immunoblotting Analyses
For in vivo samples, mice subjected to 45 minutes of ischemia followed by 4 hours or 18 hours of reperfusion, were anesthetized, injected into tail vein with 1 mmol/L Na 3 VO 4 and 2 mmol/L H 2 O 2 , and dissected to remove the left ventricle. For human umbilical artery endothelial cell experiments, 40 000 cells/cm 2 were seeded in complete culture medium (Promocell) for 72 hours. Cells were starved overnight and treated for 5 minutes with 100 ng/mL human recombinant VEGF 165 (Sigma) or with a mix containing 100 ng/mL VEGF and 5 g/mL human recombinant ANGPTL4. 12 After 2 washes with Ca 2ϩ /Mg 2ϩ PBS, proteins were extracted, immunoprecipitated for VEGFR2, and analyzed by Western blot as described in the online-only Data Supplement Materials.
Isolation of Cardiomyocytes and Viability Assay
Cardiac myocytes were isolated as described in the online-only Data Supplement Materials and incubated in an anaerobic chamber containing a humidified atmosphere of 5% CO 2 and 95% N 2 for 3 hours. Experimental medium was changed to serum-free, glucose-free. Cardiac myocyte survival was measured by staining cells with trypan blue (Sigma).
Statistical Analyses
All data were analyzed with the use of nonparametric tests. Overall comparisons were performed either by using the Kruskal-Wallis test (1 factor, 3 groups) or the Friedman test (2 factors, 2 groups). Individual comparisons were examined with a Mann-Whitney test. The use of Bonferroni correction allowed the adjustment for multiple comparisons. Differences were considered significant with *PϽ0.05.
Results

Early Postischemic Vascular Integrity Is Altered in angptl4 LacZ/LacZ Mice
Angptl4 LacZ/LacZ mice in which the angptl4 locus was replaced by a lacZ reporter gene were generated. 26 We first analyzed vascular permeability after 45 minutes of ischemia and 4 hours of reperfusion in the heart of angptl4 LacZ/LacZ and angptl4 LacZ/ϩ mice. Histological analyzes showed that tissue damage was equivalent in both groups at this early time point (data not shown). In contrast, angptl4 LacZ/LacZ mice displayed an increased vascular leakage of Evans blue dye compared with angptl4 LacZ/ϩ mice 4 hours after ischemia (117.5Ϯ8.7 versus 67.8Ϯ17 g/mL, PϽ0.05), whereas no significant difference was observed under basal conditions ( Figure 1A ). Importantly, angptl4 LacZ/LacZ mice did not exhibit functional cardiac defects (online-only Data Supplement Table I) Figure 1E and online-only Data Supplement Figure ID ). The stability of adherens junctions is critical for the maintenance of the endothelial permeability and integrity. Hence, we sought to investigate VE-cadherin distribution at endothelial adherens junctions under basal conditions and after ischemiareperfusion. In nonischemic myocardium from both genotypes, VE-cadherin linear signal labeling a dense vascular network was observed ( Figure 1B and 1C ). After ischemiareperfusion, a heterogeneous pattern of VE-cadherin staining was observed; both intense and linear signals were adjacent to thinner signals in angptl4 LacZ/ϩ mice (arrows and arrowheads, respectively, in Figure 1D and 1E). In angptl4 LacZ/LacZ mice, ischemia-reperfusion injury induced more severe damage at endothelial junctions, which were mainly disrupted as shown by more systematic discontinuous VE-cadherin staining ( These observations suggested that coronary vascular integrity was severely disrupted and junction disassembly more frequent in angptl4 LacZ/LacZ mice in comparison with angptl4 LacZ/ϩ mice after ischemia/reperfusion, thereby leading to increased vascular permeability.
Postischemic Decrease in the Expression of VEGFR2 and VE-Cadherin Combined to Increase Src Kinase Phosphorylation Downstream of VEGFR2 in angptl4 LacZ/LacZ Mice
In the vasculature, VEGFR2 and VE-cadherin form complexes that are transiently dissociated on VEGF binding to VEGFR2. During myocardial infarction, ischemia promotes VEGF expression 29 that leads to vascular permeability and edema. 30 We therefore investigated if disassembly of the VEGFR2/VE-cadherin complex might constitute the mechanism responsible for increased junctional disruption in angptl4 LacZ/LacZ mice after ischemia-reperfusion injury.
Using real-time quantitative reverse transcription polymerase chain reaction methodology, the expression of vegfr2 and ve-cadherin mRNA were quantified in the left ventricle in angptl4 LacZ/ϩ and angptl4 LacZ/LacZ mice under control conditions or after 4 or 18 hours of reperfusion. As shown in online-only Data Supplement Figure IIA , vegfr2 (left) and VE-cadherin (right) mRNA expression was similar in both groups under basal conditions. After 4 hours of reperfusion, the decrease in vegfr2 expression was more prominent in angptl4 LacZ/LacZ mice in comparison with control mice (66Ϯ5% versus 44Ϯ6% for vegfr2, PϽ0.05). VE-cadherin mRNA expression was unchanged in angptl4 LacZ/LacZ mice in comparison with control mice. Vegfr2 mRNA downregulation was maintained after 18 hours of reperfusion (decrease of 60Ϯ4% for angptl4 LacZ/LacZ mice versus 10Ϯ5% for angptl4 LacZ/ϩ mice, PϽ0.05). VEGFR2 and VE-cadherin protein levels were strongly affected at 18 hours of reperfusion as shown by Western blot analyses undertaken with the use of total extracts from left ventricles (online-only Data Supplement Figure IIB) .
Src signaling transduces VEGF-mediated permeability by dissociating the VEGFR2/VE-cadherin complex. 30 To further determine the mechanism leading to early postischemic junction alteration in angptl4 LacZ/LacZ mice, Src kinase signaling downstream of VEGFR2 was analyzed under control conditions and after ischemia-reperfusion. Left-ventricle lysates were immunoprecipitated for VEGFR2 followed by immunoblotting for VEGFR2, VE-cadherin, Src, and phospho-Src (Figure 2 ). Transient destabilization of VEGFR2/VE-cadherin complexes was observed at 4 hours of reperfusion and was restored after 18 hours of reperfusion in angptl4 LacZ/ϩ mice whereas VE-cadherin remained dissociated from VEGFR2 in angptl4 LacZ/LacZ mice at both time points (Figure 2A, top) . In addition, immunoblotting showed an increased phosphorylation of Src kinase after 18 hours of reperfusion in angptl4 LacZ/LacZ in comparison with angptl4 LacZ/ϩ mice (Figure 2A, middle and bottom, and 2B) .
These results showed that a decrease in the expression of VEGFR2 and VE-cadherin combined with an increase in the phosphorylation of Src kinase downstream of VEGFR2 lead to dissociation of the VEGFR2/VE-cadherin complex. Both events are responsible for massive disorganization of VE-cadherin in endothelial adherens junctions in angptl4 LacZ/LacZ mice after ischemia-reperfusion.
Infarct Size, No-Reflow, and Postischemic Inflammation Are Increased in angptl4 LacZ/LacZ Mice
We next hypothesized that alteration of vascular integrity in angptl4 LacZ/LacZ mice might be translated to abnormal myo- cardial reperfusion and damage to heart tissue at 48 hours of reperfusion. Indeed, infarct size was increased in angptl4 LacZ/ LacZ mice in comparison with angptl4 LacZ/ϩ mice (47Ϯ3% versus 36Ϯ3%, PϽ0.01) ( Figure 3A ). In addition, no-reflow was more important in the angptl4 LacZ/LacZ group in comparison with the angptl4 LacZ/ϩ mice if expressed as a percentage of the area at risk (19Ϯ1% versus 11Ϯ2%, PϽ0.05) (onlineonly Data Supplement Table II ). Necrosis, hemorrhage, and edema were also quantified (score 1-3) on hematoxylin and eosin-stained sections from infarcted hearts of both genotypes ( Figure 3B and 3C ). In accordance with increased infarct size, tissue necrosis was increased in angptl4 LacZ/LacZ in comparison with control mice (2.5Ϯ0.6 versus 1.2Ϯ0.2) ( Figure 3D) . Similarly, assessment of hemorrhage and edema revealed more severe tissue injury in angptl4 LacZ/LacZ mice (2.3Ϯ0.6 versus 1.1Ϯ0.2 and 2.3Ϯ0.2 versus 0.8Ϯ0.2, respectively; Figure 3D ). The postischemic inflammatory response was also analyzed in both genotypes ( Figure 3E to 3G). Macrophage density was significantly higher in infarcted areas in angptl4 LacZ/LacZ versus angptl4 LacZ/ϩ mice, whereas no statistical difference was observed between the 2 groups in noninfarcted areas ( Figure 3G ).
We then analyzed vascular density in the core infarct area and in the periphery by the use of CD31 staining ( Figure 3H and 3I). A similar diminished microcapillary density was quantified in both genotypes in the central infarcted areas in comparison with the periphery. No difference was quantified between both genotypes in both areas ( Figure 3J ).
Transmission electron microscopy study was undertaken to assess tissue injury at the ultrastructural level. Analyses of reperfused infarcted areas did not show structural differences in cardiomyocytes between the 2 groups (see C [1] [2] [3] [4] in onlineonly Data Supplement Figure IIIA and IIIB) . In contrast, large edematous areas with few inflammatory cells were observed in angptl4 LacZ/ϩ mice, whereas inflammatory cells had already invaded the edematous region in angptl4 LacZ/LacZ mice (see E in online-only Data Supplement Figure IIIC Figure  3D ). Taken together, these data indicated increased vascular alterations that correlated with increased inflammatory infiltrates in angptl4 LacZ/LacZ mice.
In addition, hypoxic activation of angptl4 mRNA has been reported in cardiomyocytes in vitro, probably mediated by hypoxia-inducible factor 1. 24 Using in situ hybridization, we demonstrated angptl4 mRNA expression in vivo in cardiomyocytes and in ECs in cardiac samples from patients who died of AMI (online-only Data Supplement Figure IV) . As in humans, in situ hybridization performed in mice subjected to ischemia-reperfusion showed that angptl4 mRNA expression was induced in cardiomyocytes and in ECs (online-only Data Supplement Figure VA and VB) . LacZ staining undertaken on hematoxylin and eosin-stained and CD31-immunostained sections and on whole mount from angptl4 LacZ/LacZ mice further confirmed expression in cardiomyocytes and ECs after ischemia-reperfusion injury (online-only Data Supplement Figure VC to VF, see arrowheads and arrows, respectively). We therefore tested the hypothesis that ANGPTL4 might affect cardiomyocyte survival in hypoxic conditions. Mouse cardiomyocytes from both genotypes were isolated and subjected to an in vitro survival assay. No difference in cardiomyocyte survival was observed in vitro between both groups in normoxia or hypoxia, suggesting that ANGPTL4 does not have a direct effect on cardiomyocytes ( Figure 3K) , thereby further suggesting it targets ECs.
Recombinant ANGPTL4 Stabilizes the VEGFR2/VE-Cadherin Complex in Response to VEGF
We next investigated if rhANGPTL4 might rescue the more severe ischemia-reperfusion-induced cardiac damage in angptl4 LacZ/LacZ mice. When injected in angptl4 LacZ/LacZ mice at 10 g/kg body weight 5 minutes before ischemiareperfusion, rhANGPTL4 reduced infarct size to 41Ϯ4% in comparison with 67Ϯ7% when mice were injected with vehicle (PϽ0.05; Figure 4A ). Remarkably, the infarct size of rhANGPTL4-injected angptl4 LacZ/LacZ mice was indistinguishable from that of control angptl4 LacZ/ϩ mice (47Ϯ2%) injected with vehicle, showing that ANGPTL4 could rescue the knockout phenotype in mice.
We then sought to define in vitro the molecular pathways responsible for rhANGPTL4-induced cardioprotection by testing if rhANGPTL4 could confer protection of disassembly of the VEGFR2/VE-cadherin complex. Confluent human umbilical artery endothelial cells were stimulated for 5 minutes with VEGF alone or with rhANGPTL4. Cell lysates were immunoprecipitated for VEGFR2 followed by immunoblotting for VEGFR2, VE-cadherin, Src, and phospho-Src. The preexisting VEGFR2/VE-cadherin observed in control conditions was rapidly disrupted within 5 minutes of VEGF stimulation. This complex was protected from dissociation in cells treated with both VEGF and rhANGPTL4 ( Figure 4B , left, and 4C). Src kinase and phospho-Src immunoblotting revealed that VEGF-mediated destabilization of the VEGFR2/VE-cadherin complex was correlated with an increased phosphorylation of Src downstream of VEGFR2 that was reduced in cells treated with both VEGF and rhANGPTL4 ( Figure 4B, right, and 4C ).
Assessment of the Therapeutic Cardioprotective Effects of rhANGPTL4 in a Nonrodent Species
We next hypothesized that attenuation of vascular alterations by rhANGPTL4 may lead to the enhancement of endothelial barrier function, which ultimately could protect ECs from ischemia-induced reperfusion injury. Myocardial ischemiareperfusion does not induce massive no-reflow in mice under these conditions, so we sought to analyze the therapeutic potential of ANGPTL4 in a nonrodent species. We chose an open-chest model of myocardial ischemia-reperfusion in rabbits, because the no-reflow phenomenon had been well established in this model. 31 We undertook intravenous injection of 10 g/kg rhANG-PTL4 or vehicle, 5 minutes before ischemia-reperfusion. Infarct size (percentage area at risk) was 57Ϯ5% in the control group and 34Ϯ7% in the rhANGPTL4-treated group (PϽ0.01; Figure 5A ). Then, the zone of no-reflow was studied. When expressed as a percentage of the area at risk, it was 41Ϯ2% in the control group and 19Ϯ6% in the rhANGPTL4-treated group (PϽ0.05; Figure 5B ). More importantly, when expressed as a percentage of the infarct size, it was 73Ϯ4% in the control group and 55Ϯ7% in the rhANGPTL4-treated group (PϽ0.05; Figure 5C ). Histological analyses showed that myocardial infarction comprised a core of necrosis and huge hemorrhage within interstitial spaces in the control group ( Figure 5D ). In the rhANGPTL4-treated group (Figure 5E ), the extent of hemorrhage was decreased (5.7Ϯ2% versus 21.9Ϯ6.4%, expressed as a percentage of total heart section area, PϽ0.05) ( Figure 5F ).
Thus, these results showed that rhANGPTL4 induced preservation of vascular integrity that reduced infarct size, hemorrhage, and no-reflow, thereby conferring cardioprotection.
Discussion
On AMI, HIF proteins, the major transcription factors involved in the regulation of responses to hypoxia, 32 are rapidly activated and induce VEGF-A expression that participates to the angiogenic response. 29 However, VEGF-A also causes vascular permeability and edema, resulting in extensive injury. 30 We showed here that angptl4 mRNA, which was previously shown to be induced by hypoxia in ECs 33 and in cardiomyocytes 24 in vitro, and in critical hindlimb ischemia and stroke, as well, 16, 34, 35 was also expressed in cardiac tissue from patients who died of AMI. In the present study, we provide evidence that ANGPTL4 mediates protection from postischemic tissue damage through preservation of the integrity of the vascular EC barrier that limits no-reflow and the extent of AMI.
In pathological ischemic conditions, increased permeability, which is controlled by endothelial junction stability, is responsible for altered vascular integrity. VE-cadherin, which constitutes the major component of the adherens junctions between ECs, is required in vivo in the postnatal vasculature to maintain the integrity and barrier function of the endothelium. 36 Yang et al 37 showed that myocardial VE-cadherin is significantly decreased in the ischemic myocardium, suggesting that microvascular integrity is damaged by ischemiareperfusion. VE-cadherin associates with VEGFR2 and regulates permeability. Indeed, systemic VEGF-A injection, thereby activating VEGFR2, induces dissociation of the VEGFR2/VE-cadherin complex. 38 Here, we showed durable dissociation of VEGFR2/VE-cadherin complexes and altered VE-cadherin distribution in angptl4 LacZ/LacZ mice that caused disrupted adherens junctions and decreased EC barrier function after AMI. Gene and protein expression analyses revealed (1) more prominent diminished VEGF and VE-cadherin levels, and (2) prolonged decrease in vegfr2 mRNA levels in angptl4 knockout mice subjected to AMI. In the heart, decreased levels VEGFR2/VE-cadherin complexes in ECs in response to ischemia might participate in junction disruptions and altered endothelial integrity after AMI in angptl4 LacZ/LacZ mice. Src is an essential molecule required for promoting the disruption of EC contacts and paracellular permeability. 38 We here provide evidence for enhanced Src kinase phosphorylation leading to more severe destabilization of the VEGFR2/VE-cadherin complex in angptl4 LacZ/LacZ mice subjected to AMI. Other members of the angiopoietin family also have a role in the regulation of vascular permeability. Angiopoietin-1 phosphorylates Tie2 and phosphatidylinositol 3-kinase, inducing activation of the GTPase Rac1, which is needed to maintain cell-cell adhesion 39 and which also activates mDia, resulting in sequestration of Src. 40 Whether regulation of Src/mDia or Rac1 signaling pathways by ANGPTL4 affects intracellular VE-cadherin distribution deserves further investigation.
Preservation of the microcirculatory network and, to a lesser extent, preservation of hemorrhage by rhANGPTL4 limited the extent of no-reflow. This phenomenon is the result of incompletely characterized anatomic changes of the coronary microcirculation 3 in which ANGPTL4 might play a crucial role through its vasculoprotective effect. In addition, reperfused myocardial infarction is associated with cellular Figure 4 . A, Infarct sizes (expressed as a percentage of the area at risk) in vehicle-injected angptl4 LacZ/ϩ , in vehicle-injected angptl4 LacZ/LacZ , and in 10 g/kg rhANGPTL4-injected angptl4 LacZ/LacZ mice. B, Western blot analyses were undertaken on HUAECs treated or not treated for 5 minutes with VEGFϮANGPTL4. Cell lysates were immunoprecipitated with an anti-VEGFR2 antibody. Graphs show VE-cadherin normalized to VEGFR2 (nϭ3 for each condition) and the ratio between Src kinase and phospho-Src normalized to VEGFR2 (nϭ4 for each condition). Data are expressed as a percentage of the control under basal conditions. Kruskal-Wallis tests followed by Mann-Whitney tests were used for comparisons. E indicates individual values; •, meanϮSEM. *PϽ0.05 indicates significantly different from respective controls. C, VEGFR2, VE-cadherin, Src kinase and phospho-Src immunoblotting. HUAEC indicates human umbilical artery endothelial cell; VEGF, vascular endothelial growth factor; VEGFR2, vascular endothelial growth factor receptor 2; IP, immunoprecipitated; IB, immunoblot.
infiltration and the acute inflammatory response. 41 A critical point in postischemic therapy is containment of the deleterious, persistent, and expanding inflammatory response. 42 We showed here that altered vascular integrity in angptl4 LacZ/LacZ mice might suppress a point of control that participates in limiting the postinfarction inflammatory response and expansion of the infarcted area.
Our results showing disorganization of endothelial adherens junctions in angptl4 LacZ/LacZ mice suggest that ANGPTL4 could promote the endothelial barrier function at multiple levels. We showed that endothelial barrier integrity was perturbed in angptl4 LacZ/LacZ mice, and that rhANGPTL4 could restore some degree of integrity and protect mice and rabbits during ischemia-reperfusion. In addition, ANGPTL4 modulates the balance between circulating triglyceride-rich lipoproteins, very-low-density lipoproteins and chylomicrons (as well as their uptake) by inhibiting endothelial lipase and lipoprotein lipase anchored at the surface of ECs. 43, 44 In angptl4 LacZ/LacZ mice, which display decreased circulating levels of triglycerides, loss of inhibition of lipoprotein lipase could lead to increased lipolysis products such as oxidized fatty acids that induce EC inflammation. 45 This could then participate in altered endothelial barrier integrity 46 and, therefore, endothelial function. 47 Elucidation of the precise mechanisms linking ANGPTL4 activity, triglyceride uptake, and potential fatty acid-induced oxidative stress 25 needs to be definitively addressed. Nevertheless, markers of oxidative stress such as fkbp5 and gsta3 were not differentially regulated in angptl4 LacZ/LacZ mice in comparison with control mice during ischemia-reperfusion (data not shown), showing that this is not likely to be the case. Alternatively, ANGPTL4mediated dysregulation of VEGF-B control of endothelial uptake of fatty acids may also be involved. 48 Finally, whereas cardiomyocytes are primarily recognized as the therapeutic target of myocardial ischemia, few studies have focused on the importance of heart vessels in this context. Clinical efforts are underway to block VEGF-Amediated leak in patients after AMI 49 or stroke. 50 The present findings show that ANGPTL4 counteracts the increase in permeability observed in reperfused AMI. This justifies the search for combined strategies that will have a significant impact on reducing tissue injury and improving the coronary microcirculation and the no-reflow phenomenon, thereby improving AMI therapy. 
